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Abstract
Objective: To explore the effects of daily use of Gerovital H3 (G.H.3.) tablets on relieving mental symptoms and
improving health-related quality of life among Chinese older adults population.
Methods: In a randomized, placebo-controlled, double-blinded study, totally 100 eligible participants were randomly
allocated into the G.H.3. group or the placebo group, administered either G.H.3. or placebo tablets and were followed up
for three months. All of the participants were required to report their subjective feelings about quality of life, low mood,
and anxiety by filling out Self-Rating Depression Scale (SDS), Self-Rating Anxiety Scale (SAS) and a 36-item Short-Form
Health Survey (SF-36 scale). Physicians were responsible for evaluating the related mental health indications through
physical examinations at the baseline and at the end of the intervention period.
Results: Participants were men and women between 50 and 89 years of age, with a median of 62.53 years. Before the
intervention, the demographic characteristics and the baseline SF-36 scores, low mood, and anxiety statuses were
comparable (p > 0.05). After the 12-week intervention, the scores of role-physical (RP), bodily pain (BP), general health
(GH), vitality (VT), mental health (MH) and health transition (HT), mental composite score (MCS) of the G.H.3. group
were higher than the placebo group
(p < 0.05), There were no significant differences in other domains in SF-36 and PCS between the two groups(p > 0.05),
the scores of SDS and SAS in the G.H.3. group were both lower than the placebo group(p < 0.01), the prevalence rates
of low moods in the G.H.3. group and the placebo group were 20.8 % and 34.0 % respectively, no significant difference
was found (χ2 =2.127,p = 0.145), while the prevalence rate of clinical anxiety concerns in the G.H.3. group was 2.1 %,
which was significantly lower than the placebo group, 22.0 % (χ2 =9.040,p < 0.001).
Conclusions: Preliminarily use of G.H.3. shows positive effects in supporting mental health and improving general
health and well-being while promoting the recovery of cognitive function among older adults. Most of SF-36 domains
including PF, RP, BP, GH, VT, RE, MH, and HT, as well as the overall quality of life in MCS might benefit from taking G.H.3.
tablets. Average levels of low moods and anxiety concerns were both reduced and the prevalence rate of clinical
anxiety concerns were reduced.
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Introduction
The quality of life in older adults is largely determined
by their functional status and health conditions [1].
Since 1999, China has entered the aging society, by
2010, China's elderly population over 60 years of age has
reached to 0.178 billion, accounting for 13.3 % of the
whole country's population, the figure of Chinese elderly
population will still increase steadily by 8 million per
year in the near future [2].
When adults enter middle-age, a reduction of intracra-
nial neurotransmitters, cerebral blood flow, cerebral oxy-
gen consumption, and catecholamine can make them
more prone to memory and cognitive dysfunction [3],
poor sleep, low moods, anxiety, frequent insomnia, fa-
tigue, dizziness, absent-mindedness, response slowly,
headaches, tinnitus, and other signs associated with
aging [4–8]. These factors can affect the quality of life in
elderly people to a large extent, and may even indirectly
lead to other chronic diseases, such as hypertension [9]
and coronary heart disease [10].
Gerovital H3 (G.H.3.) (Manufactured by Robinson
Pharma, Inc., Orange County, CA, USA) is a nutritional
supplement that may provide potential effects in im-
proving mental health and improving health-related
quality of life. The current experiment performed was a
randomized, double-blind, placebo-controlled study con-
ducted on older adults in China experiencing at least
one of the following symptoms/complaints which in-
cluded anxiety, inattention, memory decline, insomnia,
self-induced fatigue, sleepiness, slow responses, involun-
tary staring, absent-mindedness, vertigo, dizziness, head-
aches, tinnitus, palpitations, chest pain, etc.
As the first G.H.3. randomized controlled trial(RCT)
research conducted on Chinese older adults populations,
the objective of this study was to explore the effects of
daily use of G.H.3. tablets in improving mental health
and improving health-related quality of life.
Methods
Subjects
A total of 122 participants were recruited from the
outpatient department of Jiaxing Community Health
Service Center, Hongkou District, Shanghai, China, from
November 19, 2011, to December 21, 2011.
All of the participants were men and women over
50 years old who had at least one of the related complaints
associated with mental health and health-related life
quality decline which included anxiety, inattention,
memory decline, insomnia, self-induced fatigue, sleepiness,
response slowly, involuntary staring, absent-mindedness,
vertigo, dizziness, headaches, tinnitus, palpitations, chest
pain, etc. The study excluded 16 individuals who had
Alzheimer’s Disease, severe depression, mental illness,
cancer of any type, history of any severe disease diagnosis
(including severe diabetes, cardiovascular disease, etc.)
or those currently (within 30 days) taking any prescrip-
tion or over-the-counter drugs that may affect neuroen-
docrine function. We also excluded 6 individuals who
were eligible but had refused to join the study, so there
were totally 100 participants took part in this random-
ized, placebo-controlled, double-blinded study at the
beginning.
Using random number tables, the 100 participants
who met all the eligibility criteria provided written, in-
formed consent prior to the study and were randomly
allocated into the G.H.3. group (Experimental, n = 50) or
the placebo group (Control, n = 50) with simple
randomization method. Participants were administered
either G.H.3. or placebo tablets and were followed up
for three months. The determination of sample size was
mainly based on the limitations of research period and
research funds.
Intervention
Each participant in both groups received a container
marked with different-colored labels (which was blinded
for both subjects and researchers) and detailed instruc-
tions for administrating the tablets. The unmasking was
done at the end of the intervention.
The G.H.3. and the placebo tablets were both provided
by Robinson Pharma, Inc (Orange County, CA, USA).
Participants in the experimental group (G.H.3. group)
and in the control group (placebo group) both took two
placebo tablets orally, once daily. The active components
of the G.H.3. tablets were comprised of Vitamin A, vita-
min C, vitamin E, vitamin B1, vitamin B2, vitamin B3,
vitamin B6, folic acid, vitamin B12, calcium, magnesium,
zinc, selenium, chromium, St. John’s wort (Hypericum
perforatum), Dimethylaminoethanol (DMAE), para-
aminobenzoic acid (PABA), Ginkgo biloba, and L-
glutathione. The main ingredient of the placebo tablets
was flour.
The total intervention period lasted for 12 weeks. Two
subjects in the G.H.3. group dropped out in the first
month, because their relatives refused to let them con-
tinue taking the tablets, resulting in 98 participants
remaining who were followed up once per month. Tab-
lets were dispensed with follow-ups. All follow-ups for
both the G.H.3. group and the placebo group were com-
pleted on March 14, 2012. A total of 98 cases completed
the last follow-up and final survey, (48 cases in the
G.H.3. group, 50 cases in the placebo group) (see Fig. 1).
Assessment of outcomes
All patients were required to complete a questionnaire
which recorded their date of birth, gender, ethnicity,
medical history, smoking history, alcohol intake history,
medical history, current medication(s), and complaints
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relating to mental health at the baseline. All of the par-
ticipants were also required to report their subjective
feelings about quality of life, low moods, and current
anxiety levels (within past week) by filling out three
measurement scales which included surveys for Self-
Rating Depression Scale (SDS), Self-Rating Anxiety Scale
(SAS) and a 36-item Short-Form Health Survey (SF-36
scale) at the beginning of enrollment and one week after
they finished taking all of the tablets.
At the baseline and at the end of the intervention
period, physicians evaluated the related mental health
indicators (including anxiety, inattention, memory decline,
insomnia, self-induced fatigue, sleepiness, involuntary
staring, slow responses, absent-mindedness, excessive use
of brains, forgetfulness, vertigo, dizziness, headaches,
tinnitus) for each participant through physical examina-
tions, assigning scores ranging from 1 to 5, with 1 indicat-
ing the absence of a given concern and 5 indicating a
severe degree of that specific concern. In order to evaluate
the magnitude of symptom improvements among the par-
ticipants in the G.H.3. group, we figured out the score
changes of the same person before and after intervention.
If the score of a mental health indicator after three-month
follow-up reduced by 1 point or more compared to the
beginning of the intervention, it was defined as an
improvement.
The SDS and SAS scales each contain 20 items reflect-
ing different indications of low mood and anxiety [11]
and use a 4-point scoring method, participants gave an
answer according to whether the item has occurred and
its frequency: 1 = never/very rarely/rarely; 2 = once in a
while/some of the time/occasionally; 3 = relatively often/
very often/often; 4 =most of the time/always/almost
always [12]. The original total scores of low moods and
anxiety were obtained by summing up all of the scores
of these 20 items (rang 20–80), then we converted them
into SDS scores and SAS scores by using original score ×
1.25(rang 25–100) [13]. Higher SDS scores and SAS
scores generally reflected more serious levels of low
moods and anxiety concerns. [14] The cutoff point of
SAS score 50 and SDS score 53 considered as the pres-
ence of clinical anxiety concern and low moods respect-
ively in Chinese population [15]. Several domestic and
international research results show that both SDS and
SAS surveys have high reliability and validity [16–18].
The SF-36 scale is a widely recognized health-related,
quality-of-life (HRQoL) assessment tool used in Europe
and America to evaluate both physical and mental health
[19]. SF-36 scale includes eight domains, including phys-
ical functioning (PF), role-physical (RP), bodily pain
(BP), general health (GH), vitality (VT), social function-
ing (SF), role-emotional (RE), and mental health (MH).
Fig. 1 Flow diagram of the study design
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In addition, there is a single-item indicator—health transi-
tion (HT) to assess the health changes in the past year [20].
Items were summed per domain and transformed into
scores between 0–100, with higher values representing bet-
ter function [21]. Physical composite score (PCS) and men-
tal composite score (MCS) were calculated according to
each domain score and the data of Chinese adults model
[22]. PCS was significantly associated with chronic disease,
walking ability, visual ability, sleep quality, marital status, al-
cohol consumption, hearing ability, smoking, neighborhood
relationships, filial piety, ethnicity, and dietary habits. MCS
was associated with chronic disease, sleep quality, walking
ability, visual ability, marital status, ethnicity, filial piety,
dietary habits, alcohol consumption, smoking, and hearing
ability [2].
Along with the follow-ups, self-reported side effects and
adherences were recorded.
The primary outcomes included the scores of the eight
domains in SF-36(PF, RP, BP, GH, VT, SF, RE, MH), the
single-item indicator—HT and the side effects. The sec-
ondary outcomes included the scores of PCS, MCS,
SDS, SAS, the prevalence rate of low moods, the preva-
lence rate of clinical anxiety concerns and the improve-
ment rates on the scores of mental symptoms.
Statistical analysis
EpiData 3.02 software was used to establish the database.
SPSS 20.0 software was used for statistical analysis. Vari-
ables were compared between the two groups by apply-
ing Student’s t-test for quantitative variables and Chi-
square test for categorized variables. The alpha level
chosen was 0.05. All p-values reported were 2-sided.
Results
Baseline data
The baseline demographic characteristics
Participants were men and women between 50 and
89 years of age, with a median of 62.53 years. The base-
line demographic characteristics between the two groups
were comparable on age, gender, alcohol intake history,
etc. (see Table 1).
Comparisons on SF-36 scores at baseline
The PCS, MCS, and scores of each domain between the
G.H.3. group and the placebo group were compared and
there was no significant difference being found (see
Table 2).
Comparisons on low moods and anxiety statuses at
baseline
Before the intervention, there was no significant differ-
ence between the G.H.3. group and the placebo group in
the scores of SDS and SAS (see Table 2).
The prevalence rates of low moods in the G.H.3. group
and the placebo group were 56.3 % (27/48) and 52.0 %
(26/50) respectively, with no significant difference
(χ2 =0.178,p = 0.673). And the prevalence rates of clinical
anxiety concerns in the G.H.3. group and the placebo
group were 41.7 % (20/48) and 40.0 % (20/50) respectively,
with no significant difference either(χ2 =0.028,p = 0.867).
Results after intervention
Comparisons on SF-36 scores after the intervention
This study also showed that participants in the G.H.3.
group experienced better quality of life after taking
the G.H.3. tablets compared to those taking the pla-
cebo. After the 12-week intervention, the score of RP
in the G.H.3. group was 77.60 ± 35.45, which was sig-
nificantly higher than the score (60.00 ± 38.13) in the
placebo group (p = 0.020). The score of BP in the
G.H.3. group was 81.25 ± 11.23 and was also signifi-
cantly higher than the score (75.40 ± 14.17) in the pla-
cebo group (p = 0.026). The score of GH in the
G.H.3. group was 56.77 ± 18.49 and was also signifi-
cantly higher than the score (46.20 ± 17.63) in the pla-
cebo group (p = 0.005). The score of VT in the G.H.3.
group was 72.92 ± 12.88 and was also significantly
higher than the score (62.10 ± 17.16) in the placebo
group (p = 0.001). There were also significant differ-
ences in the scores of MH and HT between the two
groups. The score of MCS in the G.H.3. group was
higher than which in the placebo group (p = 0.011).
There was insufficient evidence to distinguish the ef-
fects of G.H.3. from the placebo for other domains
and PCS (see Table 3).
Table 1 Demographic characteristics for the G.H.3. group and
the placebo group at baseline
Demographic
characteristics






Male 21(43.8) 19(38.0) 40(40.8) χ2 =0.335,p =
0.563
Female 27(56.2) 31(62.0) 58(50.2)
Age group(in
years)
50-59 16(33.3) 18(36.0) 34(34.7) χ2 =0.139,p =
0.933
60-69 17(35.4) 16(32.0) 33(33.7)
70- 15(31.3) 16(32.0) 31(31.6)
Alcohol intake
Yes 12(25.0) 8(16.0) 20(20.4) χ2 =1.221,p =
0.269
No 36(75.0) 42(84.0) 78(79.6)
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Comparisons on low moods and anxiety after the
intervention
After the intervention, the scores of SDS and SAS in the
G.H.3. group were both lower than the placebo group (see
Table 3).
The prevalence rate of low moods in the G.H.3. group
was 20.8 % (10/48), no significant difference was found in
the prevalence rate of the placebo group, which was 34.0
% (17/50) (χ2 =2.127,p = 0.145), while the prevalence rate
of clinical anxiety concerns in the G.H.3. group was
2.1 %(1/48), which was significantly lower than which in
the placebo group, 22.0 % (11/50), (χ2 =9.040,p < 0.001).
The changes before and after the intervention in the
G.H.3. group
SF-36 scores
All of the eight-domain scores in SF-36 were signifi-
cantly improved in the G.H.3. group as were the scores
for PCS and MCS(see Table 4) after the intervention.
Low mood and anxiety statuses
The scores of SDS and SAS in the G.H.3. group were
both reduced significantly after the intervention (see
Table 4).
The improvement rates on the scores of mental health
indicators
We found that there were totally six indicators of which
improvement rates exceeding 50 %, including insom-
nia(60.4 %), dizziness(60.4 %), memory decline(54.2 %),
self-induced fatigue(54.2 %), forgetfulness(52.1 %), and
inattention(50.0 %).
Side effects
No serious, adverse reaction from taking G.H.3. was found
in the study, only one participant(Male, 58 years old) in the
G.H.3. group reported that he had felt a slight bloating and
nausea occasionally after taking G.H.3., but it was not ser-
ious and the concerns were soon relieved. One other per-
son (Female, 59 years old) in the placebo group reported
that she had felt a mild headache.
Discussion
China has the world’s largest elderly population, mean-
while, the proportion of the elderly population continues
to increase, the burden of the elderly related diseases are
becoming more and more serious at the same time, for
Table 2 Comparisons on SF-36, SDS and SAS scores at baseline
Domain Average scores (XS) t p-
valueG.H.3. (n = 48) Placebo (n = 50)
PF 69.27 ± 26.62 73.10 ± 27.14 −0.705 0.483
RP 41.67 ± 42.32 46.50 ± 41.04 −0.574 0.567
BP 70.42 ± 14.14 72.20 ± 15.82 −0.588 0.558
GH 42.71 ± 19.16 43.20 ± 18.32 −0.130 0.897
VT 56.46 ± 22.14 57.30 ± 20.21 −0.197 0.845
SF 66.41 ± 24.48 69.00 ± 21.91 −0.553 0.581
RE 45.14 ± 39.79 51.33 ± 38.81 −0.780 0.437
MH 57.58 ± 21.26 58.32 ± 19.23 −0.180 0.857
HT 36.98 ± 23.06 35.50 ± 17.56 0.358 0.721
PCS 40.61 ± 13.52 42.11 ± 14.57 −0.525 0.600
MCS 35.02 ± 17.93 36.14 ± 17.02 −0.318 0.751
SDS 54.97 ± 12.27 53.03 ± 11.16 0.823 0.412
SAS 48.88 ± 11.86 46.00 ± 10.22 1.289 0.200
Table 3 Comparisons on SF-36, SDS and SAS scores after the
intervention
Domain Average scores (XS) t p-
valueG.H.3. (n = 48) Placebo (n = 50)
PF 75.73 ± 22.17 72.90 ± 24.68 0.596 0.552
RP 77.60 ± 35.45 60.00 ± 38.13 2.365 0.020
BP 81.25 ± 11.23 75.40 ± 14.17 2.259 0.026
GH 56.77 ± 18.49 46.20 ± 17.63 2.897 0.005
VT 72.92 ± 12.88 62.10 ± 17.16 3.544* 0.001
SF 75.78 ± 23.55 70.50 ± 22.69 1.131 0.261
RE 81.25 ± 31.44 67.33 ± 38.39 1.959 0.053
MH 71.33 ± 13.96 62.16 ± 14.88 3.144 0.002
HT 53.65 ± 23.06 44.00 ± 20.55 2.188 0.031
PCS 45.88 ± 12.62 42.92 ± 14.23 1.088 0.279
MCS 48.09 ± 9.89 41.23 ± 15.73 2.596* 0.011
SDS 42.79 ± 8.65 49.68 ± 10.52 −3.532 0.001
SAS 37.89 ± 7.08 43.68 ± 8.42 −3.675 0.000
*: t’-test
Table 4 The changes of SF-36, SDS and SAS scores before and
after the intervention in the G.H.3. group
Domain Before (n = 48) After (n = 48) Difference t p-value
PF 69.27 ± 26.62 75.73 ± 22.17 6.46 ± 18.76 2.385 0.021
RP 41.67 ± 42.32 77.60 ± 35.45 35.94 ± 44.03 5.654 0.000
BP 70.42 ± 14.14 81.25 ± 11.23 10.83 ± 13.18 5.694 0.000
GH 42.71 ± 19.16 56.77 ± 18.49 14.06 ± 17.28 5.638 0.000
VT 56.46 ± 22.14 72.92 ± 12.88 16.46 ± 22.64 5.036 0.000
SF 66.41 ± 24.48 75.78 ± 23.55 9.38 ± 25.46 2.551 0.014
RE 45.14 ± 39.79 81.25 ± 31.44 36.11 ± 38.80 6.449 0.000
MH 57.58 ± 21.26 71.33 ± 13.96 13.75 ± 23.18 4.110 0.000
HT 36.98 ± 23.06 53.65 ± 23.06 16.67 ± 22.08 5.229 0.000
PCS 40.61 ± 13.52 45.88 ± 12.62 5.27 ± 10.44 3.497 0.001
MCS 35.02 ± 17.93 48.09 ± 9.89 13.07 ± 16.43 5.515 0.000
SDS 54.97 ± 12.27 42.79 ± 8.65 −12.19 ± 15.11 −5.588 0.000
SAS 48.88 ± 11.86 37.89 ± 7.08 −10.99 ± 14.54 −5.237 0.000
*: Paired-samples t-test
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exsample, the results of some meta analyses show that the
prevalence of clinical anxiety symptom and clinical depres-
sion symptom among the elderly in China has reached to
22.1 % [23] and 22.6 % [24], respectively. According to sleep
disorder, the prevalence has even reached to 47.2 % [25],
while sleep disorder was reported as a major risk factor of
the morning peak phenomenon for an elderly patient with
simple systolic hypertension, so improving the sleep quality
is extremely essential for older people [26]. Maintaining
and improving the quality of life of the elderly has also
emerged as a particularly important issue [27].
G.H.3. was found to have positive effects in im-
proving parts of mental health indicators such as in-
attention, memory decline, insomnia, self-induced
fatigue, response slowly, absent-mindedness, forget-
fulness, dizziness, headaches, etc. The lessening of
these indicators will bring great benefits for the gen-
eral health and state of well-being among older
adults population. Between all of the related mental
health indicators, insomnia was the most obviously
improved. As mentioned earlier, improving sleep
quality and reducing the frequency of sleep disorder
is potentially very useful for the control of systolic
blood pressure level in the morning, and the reduc-
tion of the cardiovascular events occurrence among
elderly. The improvements of the memory decline,
forgetfulness and inattention will potentially promote
the recovery of cognitive function for the older
adults and reduce the care giving burden of their
families and communities.
It was also observed that most SF-36 domains including
PF, RP, BP, GH, VT, RE, MH, and HT might benefit from
taking G.H.3. tablets. MCS was found not only a significant
difference between the G.H.3. group and the placebo group
after the intervention, but also a great increase in the same
G.H.3. group before and after, it indicates that mental
health status might actually get improved after exclusion of
placebo effect. Generally, PCS does not exhibit a significant
difference between the G.H.3. group and the placebo group
after the intervention, so there is no evidence can prove
G.H.3. tablets help to improve physical health status in
general.
G.H.3. preliminarily exhibited potent effects in improv-
ing the general degrees of low moods and anxiety con-
cerns among older adults. It might also help to reduce
prevalence rate of clinical anxiety concerns, but we didn’t
observed that G.H.3. tablets could help to reduce preva-
lence rate of low moods. Due to these benefits mentioned
above we may expect that the incidence risk of some
chronic diseases, such as hypertension and coronary heart
disease will be lowered indirectly to some extent.
Taking two tablets of G.H.3. orally once daily is consid-
ered to be safe due to no serious, adverse reaction being
observed during the whole follow-up period in this study.
Limitation
There were several limitations in this study. Firstly, be-
cause the outcome measured in this research was mainly
based on subjective symptoms, the judgment of interven-
tion effects could be easily influenced by psychological
effects of the subjects and the researchers. Improvements
of indicators in the placebo group after the intervention
showed this effect, but the strict using of randomization,
placebo-control, and double-blinded methods ensured a
relatively higher validity of the results in this study.
Secondly, some potential confounding factors—such
as weight, lifestyle, and dietary habits—were not con-
trolled in the study. But as the two groups were well-
balanced in the baseline characteristics, we expected that
the effects of differences in these, or other potential con-
founding factors, are minimal.
Thirdly, the information from SF-36, SDS, SAS were
obtained based on the participants’ recall, recall errors
might exist, however, since the two groups had good
comparability due to the double-blinded design, the pos-
sibility of recall bias should be relatively low.
Fourthly, all of our participants were volunteers, i.e.
those eligible who did not wish to participate were ex-
cluded. If those who were excluded were not exactly
compatible with those enrolled for the study, the results
would suffer a selection bias.
Finally, because of the limitation of the study period
and the sample size, which ensured a high hypothesis
testing level(0.05), the efficiency of some hypothesis tests
may not be very high.
The research has achieved the expected research pur-
poses, G.H.3. preliminarily shows positive effects in improv-
ing parts of mental health, the average levels of low moods
and anxiety concerns in participants, as well as improving
general health-related quality of life factors, particularly in
mental health levels among older adults. Further study is
needed to confirm these inferences to a greater extent.
Conclusions
In summary, G.H.3. preliminarily shows positive effects in
improving parts of mental health such as inattention,
memory decline, insomnia, self-induced fatigue, slow re-
sponse, absent-mindedness, forgetfulness, dizziness, head-
aches, etc. and improving the general health and state of
well-being, which promotes the cognitive function among
older adults. Most of SF-36 domains including PF, RP, BP,
GH, VT, RE, MH, and HT, as well as the overall quality of
life in MCS might get benefit from taking G.H.3. tablets.
The average levels of low moods and anxiety concerns
were both relieved and the prevalence rate of clinical anx-
iety concern was reduced as well. No serious, adverse re-
actions from taking G.H.3. were found in this study.
These results may assist physicians in determining its
clinical applications.
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